HYPOPHOSPHATASIA

In HPP, an inheritied enzyme defect leaves bone unable to mineralize

Cause
Loss-of-function ALPL mutations reduce TNAP enzyme activity, allowing accumulation of excess PPi

Clinical manifestations
Accumulated PPi blocks bone mineralization, leading to rickets or osteomalacia, fractures and pseudofractures, bone pain, and premature tooth loss

Approach
AN2-504661 was designed for HPP: optimized for chronic, titratable dosing to bring PPi into the normal range

Hypophosphatasia (HPP) is a rare, inherited metabolic bone disease caused by loss-of-function mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNAP). TNAP deficiency allows inorganic pyrophosphate (PPi), a potent inhibitor of bone mineralization, to accumulate.

 

Deficient TNAP lets PPi accumulate

How PPi is regulated

Diagram comparing PPi regulation in healthy individuals and HPP. In healthy individuals, ENPP1 converts ATP to PPi, and TNAP clears PPi to phosphate (Pi). In HPP, ALPL mutations reduce TNAP activity, so PPi builds up instead of being cleared to phosphate.

PPi must land in a window

Diagram showing PPi levels on a scale from the target range to high PPi. Untreated HPP sits in the high PPi range, and titrated ENPP1 inhibition moves PPi back toward the target range. The healthy range supports normal bone mineralization with no unwanted calcification and is the titration target. Too much PPi blocks hydroxyapatite formation, leading to weak bones, fractures and pain (HPP).

HPP encompasses a spectrum of disease ranging from life-threatening perinatal and infantile forms to adult-onset disease characterized by fractures, chronic pain, muscle weakness, impaired mobility, and other serious complications throughout life. The only U.S.-approved therapy for HPP is an enzyme replacement therapy (ERT) indicated only for patients with perinatal/infantile or juvenile-onset HPP. It requires subcutaneous injections.

 

Inhibiting ENPP1 may reduce PPi production at its source
Because ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is the principal enzyme that generates extracellular PPi, we believe that inhibiting ENPP1 may reduce PPi production at its source, normalize PPi levels, and improve bone mineralization. We have selected AN2-504661, an oral, boron-based inhibitor of ENPP1, as our development candidate for the treatment of HPP. AN2-504661 has demonstrated the potential for a differentiated profile characterized by potent and selective ENPP1 inhibition, favorable pharmacokinetic properties and oral bioavailability, efficacy in animal models, and an encouraging nonclinical safety profile with low potential for hERG-related cardiac events and other safety liabilities, supporting its potential to be best-in-class.

Preclinical highlights

Potent
Low-nM inhibition of ENPP1

Selective
≥100-fold vs. ENPP3 and other ENPPs

Oral & titratable
High oral bioavailability across species; PK/PD-driven dosing

Early safety data
No hERG liability; strong AUC margins; non-genotoxic

Potent
Low-nM inhibition of ENPP1

Selective
≥100-fold vs. ENPP3 and other ENPPs

Oral & titratable
High oral bioavailability across species; PK/PD-driven dosing

Early safety data
No hERG liability; strong AUC margins; non-genotoxic